Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India’s Glenmark Establishes Unit In Romania

This article was originally published in PharmAsia News

Executive Summary

India's Glenmark Pharmaceuticals has established a new unit in Romania to produce specialty drugs. Glenmark sees a $50 million market in Romania within the next five years. Romania recently was admitted into the European Union and becomes the third European country to see a Glenmark unit established. (Click here for more

You may also be interested in...

India’s Glenmark Continues Push Into European Markets

MUMBAI - Indian drug maker Glenmark Pharmaceuticals will launch a division in Poland by acquiring seven generic pharmaceutical brands from Actavis, the Iceland-based generics major, and its Polish affiliate Biovena. The buy provides Glenmark an entry into the Polish market, estimated to be the largest in Central and East Europe

Ahead Of Ryoncil’s Advisory Committee, Citizen Petition Opposes Approval For Pediatric GVHD

Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.

Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH

Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts